Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized Trial. Academic Article uri icon



  • Background: Maraviroc (MVC) is a candidate drug for HIV preexposure prophylaxis (PrEP). Objective: To assess the safety and tolerability of MVC-containing PrEP over 48 weeks in U.S. women at risk for HIV infection. Design: Phase 2 randomized, controlled, double-blinded study of 4 antiretroviral regimens used as PrEP. ( NCT01505114). Setting: 12 clinical research sites of the HIV Prevention Trials Network and AIDS Clinical Trials Group. Participants: HIV-uninfected women reporting condomless vaginal or anal intercourse with at least 1 man with HIV infection or unknown serostatus within 90 days. Intervention: MVC only, MVC-emtricitabine (FTC), MVC-tenofovir disoproxil fumarate (TDF), and TDF-FTC (control). Measurements: At each visit, clinical and laboratory (including HIV) assessments were done. Primary outcomes were grade 3 and 4 adverse events and time to permanent discontinuation of the study regimen. All randomly assigned participants were analyzed according to their original assignment. Results: Among 188 participants, 85% completed follow-up, 11% withdrew early, and 4% were lost to follow-up; 19% discontinued their regimen prematurely. The number discontinuing and the time to discontinuation did not differ among regimens. Grade 3 or 4 adverse events occurred in 5 (MVC), 13 (MVC-FTC), 9 (MVC-TDF), and 8 (TDF-FTC) participants; rates did not differ among regimens. One death (by suicide) occurred in the MVC-TDF group but was judged not to be related to study drugs. Of available plasma samples at week 48 (n = 126), 60% showed detectable drug concentrations. No new HIV infections occurred. Limitations: Participants were not necessarily at high risk for HIV infection. The regimen comprised 3 pills taken daily. The study was not powered for efficacy. Conclusion: Maraviroc-containing PrEP regimens were safe and well-tolerated compared with TDF-FTC in U.S. women. No new HIV infections occurred, although whether this was due to study drugs or low risk in the population is uncertain. Maraviroc-containing PrEP for women may warrant further study. Primary Funding Source: National Institutes of Health.


  • Gulick, Roy M
  • Wilkin, Timothy
  • Chen, Ying Q
  • Landovitz, Raphael J
  • Amico, K Rivet
  • Young, Alicia M
  • Richardson, Paul
  • Marzinke, Mark A
  • Hendrix, Craig W
  • Eshleman, Susan H
  • McGowan, Ian
  • Cottle, Leslie M
  • Andrade, Adriana
  • Marcus, Cheryl
  • Klingman, Karin L
  • Chege, Wairimu
  • Rinehart, Alex R
  • Rooney, James F
  • Andrew, Philip
  • Salata, Robert A
  • Siegel, Marc
  • Manabe, Yukari C
  • Frank, Ian
  • Ho, Ken
  • Santana, Jorge
  • Stekler, Joanne D
  • Swaminathan, Shobha
  • McCauley, Marybeth
  • Hodder, Sally
  • Mayer, Kenneth H

publication date

  • August 22, 2017



  • Cyclohexanes
  • HIV Fusion Inhibitors
  • HIV Infections
  • Pre-Exposure Prophylaxis
  • Triazoles


PubMed Central ID

  • PMC5667908

Scopus Document Identifier

  • 85029682296

Digital Object Identifier (DOI)

  • 10.7326/M17-0520

PubMed ID

  • 28828489

Additional Document Info


  • 167


  • 6